Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Response rates--an evolution

E Poplin1, L Baker

  • 1Wayne State University, Division of Hematology and Oncology, Detroit, MI 48201.

Cancer Chemotherapy and Pharmacology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A standard operating procedure for reducing risk from medications prohibited during clinical trials in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

The influence of miscentering on radiation dose during computed tomography head examinations and the role of localiser orientation: A phantom study.

Radiography (London, England : 1995)·2024
Same author

Mortality in extreme heat events: an analysis of Los Angeles County Medical Examiner data.

Public health·2024
Same author

Yield of brain MRI in children with autism spectrum disorder.

European journal of pediatrics·2023
Same author

Disease-specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot-Marie-Tooth disease type 1A.

Journal of the peripheral nervous system : JPNS·2023
Same author

The Impact of an Electronic Prescribing Template with Decision Support upon the Prescribing of Subcutaneous Infusions at the End of Life in a Community Setting: A Future Vision for Community Palliative Care.

Pharmacy (Basel, Switzerland)·2022
Same journal

Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

Cancer chemotherapy and pharmacology·2026
Same journal

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
See all related articles

Cancer treatment effectiveness may be declining due to changes in trial criteria and reporting biases. Careful review of older chemotherapy trial data is now recommended for accurate efficacy assessment.

Area of Science:

  • Oncology
  • Clinical Trials
  • Chemotherapy Research

Background:

  • Documented response rates to chemotherapy have seemingly decreased over recent decades.
  • Several factors may contribute to this observed decline in treatment efficacy.

Purpose of the Study:

  • To analyze the potential reasons behind the decreasing frequency of cancer response to chemotherapy.
  • To highlight biases that may affect the interpretation of chemotherapy trial data.

Main Methods:

  • Review of historical trends in cancer clinical trial eligibility and response assessment criteria.
  • Analysis of factors influencing patient selection and data evaluation in chemotherapy studies.
  • Examination of publication bias related to negative trial outcomes.

Related Experiment Videos

Main Results:

  • Changes in eligibility, evaluability, and response criteria have impacted reported outcomes.
  • Patient population shifts and altered response assessment methods contribute to perceived efficacy decline.
  • The tendency to not publish negative results creates an overestimation bias for drug efficacy.

Conclusions:

  • The apparent decrease in chemotherapy response rates necessitates critical evaluation of historical data.
  • Researchers and clinicians should exercise caution when interpreting findings from older chemotherapy trials.
  • Understanding methodological and reporting changes is crucial for accurate cancer drug efficacy assessment.